Bowman & Co S.C. Has $1.01 Million Stock Holdings in DexCom, Inc. $DXCM

Key Points

• Bowman & Co S.C. increased its holdings in DexCom, Inc. by 64% during the 2nd quarter, now owning 11,566 shares valued at approximately $1.01 million.
• Multiple hedge funds have recently adjusted their positions in DexCom, with some like Brighton Jones LLC increasing their stakes by over 250%.
• A range of analysts have set new price targets for DexCom, with most maintaining buy ratings and a consensus price target of approximately $99.89.

Bowman & Co S.C. increased its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 64.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,566 shares of the medical device company's stock after acquiring an additional 4,512 shares during the period. Bowman & Co S.C.'s holdings in DexCom were worth $1,010,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in DXCM. Brighton Jones LLC boosted its position in DexCom by 257.7% in the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company's stock valued at $1,290,000 after buying an additional 11,946 shares in the last quarter. Bank Pictet & Cie Europe AG boosted its position in DexCom by 1.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 111,063 shares of the medical device company's stock valued at $8,637,000 after buying an additional 2,010 shares in the last quarter. Focus Partners Wealth acquired a new stake in DexCom in the fourth quarter valued at approximately $496,000. Snowden Capital Advisors LLC boosted its position in DexCom by 23.4% in the fourth quarter. Snowden Capital Advisors LLC now owns 8,170 shares of the medical device company's stock valued at $635,000 after buying an additional 1,548 shares in the last quarter. Finally, State of Wyoming boosted its position in DexCom by 3,522.0% in the fourth quarter. State of Wyoming now owns 1,811 shares of the medical device company's stock valued at $141,000 after buying an additional 1,761 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Insider Activity

In other news, EVP Sadie Stern sold 1,466 shares of the company's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $88.99, for a total transaction of $130,459.34. Following the transaction, the executive vice president owned 106,689 shares in the company, valued at approximately $9,494,254.11. This represents a 1.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Mark G. Foletta sold 2,750 shares of the company's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $81.06, for a total transaction of $222,915.00. Following the transaction, the director owned 51,121 shares in the company, valued at $4,143,868.26. This represents a 5.10% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 8,315 shares of company stock worth $689,431 in the last three months. Corporate insiders own 0.32% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on DXCM. Truist Financial began coverage on shares of DexCom in a research report on Monday, June 16th. They issued a "buy" rating and a $102.00 target price on the stock. Citigroup reaffirmed a "buy" rating and set a $102.00 price target (up previously from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. Argus assumed coverage on shares of DexCom in a research note on Thursday, August 21st. They set a "buy" rating and a $100.00 price target for the company. Raymond James Financial raised their price target on shares of DexCom from $99.00 to $102.00 and gave the company a "strong-buy" rating in a research note on Thursday, July 31st. Finally, The Goldman Sachs Group assumed coverage on shares of DexCom in a research note on Friday, May 30th. They set a "buy" rating and a $104.00 price target for the company. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $99.89.

DexCom Price Performance

DXCM stock opened at $75.58 on Tuesday. The firm has a market cap of $29.64 billion, a price-to-earnings ratio of 52.49, a PEG ratio of 1.60 and a beta of 1.48. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $93.25. The company's fifty day simple moving average is $80.73 and its 200 day simple moving average is $78.49.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.03. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. DexCom's revenue for the quarter was up 15.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. On average, analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.